
Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target
Vanda Pharmaceuticals (VNDA) Analyst Ratings
Bulls say
Vanda Pharmaceuticals is expected to see a positive financial outlook in the coming years, driven by its strong commercial portfolio and a robust pipeline of therapeutics targeting various unmet medical needs. The company is currently focusing on expanding its presence in the US market and has a promising outlook for its Fanapt product, which generates the maximum revenue. Its other products also show potential for growth, including ASO molecules and VTR-297. Overall, Vanda Pharmaceuticals has strong opportunities for revenue growth and value creation, supported by its ongoing late-stage clinical trials and potential upcoming approvals.
Bears say
Vanda Pharmaceuticals is facing significant clinical and development risks as the success of their pipeline is heavily dependent on FDA approval. Financially, the company may need additional capital to fund further research and development which could negatively impact their cash balance and earnings. Furthermore, the company has faced product liability claims which could result in financial losses. These risks, combined with a headline revenue miss, make us reiterate our negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Vanda Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Vanda Pharmaceuticals (VNDA) Analyst Forecast & Price Prediction
Start investing in Vanda Pharmaceuticals (VNDA)
Order type
Buy in
Order amount
Est. shares
0 shares